ferumoxytol (Feraheme, ferrosoferric oxide)
Jump to navigation
Jump to search
Indications
- iron replacement in anemia of chronic kidney disease & iron-deficiency anemia
- useful as MRI contrast agent[3]
Dosage
- intravenous iron replacement
- given by IV push in just 2 doses of 510 mg 3-8 days apart
Injection: 30 mg/mL (elemental iron) solution for injection in 17 mL vials containing 510 mg of elemental iron.
Adverse effects
Mechanism of action
- superparamagnetic form of iron oxide, with a carbohydrate shell
- contains iron nanoparticle
More general terms
References
- ↑ Prescriber's Letter 16(9): 2009 New Drug: Feraheme (Ferumoxytol) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250913&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Prescriber's Letter 17(2): 2010 New Drugs Approved by the FDA in 2009 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260213&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Klenk C et al Ionising radiation-free whole-body MRI versus 38F-fluorodeoxy- glucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. The Lancet Oncology, Early Online Publication, 19 February 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24559803 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970021-X/abstract
- ↑ 4.0 4.1 FDA Drug Safety Communication: March 30, 2015 FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm